{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'modifications not specified below (e.g., severe or cumulative cutaneous reactions) and', 'starting doses should also consider local product label or SmPC and institutional guidelines.', 'Table 7', 'Recommended Docetaxel Dose Modification Guidelines', 'Dose', 'Discontinue', 'Toxicity', 'Grade', 'Occurrence', 'Hold Treatment', 'Modification', 'Treatment', 'Peripheral', 'Grade 1, 2', 'No', '60 mg/m\u00b2', 'N/A', 'Neuropathy', 'Grade 3, 4', 'Yes', 'N/A', 'Discontinue', 'upon onset', 'Neutropenic fever', '1', 'Hold treatment', '60 mg/m\u00b2', '(defined as T', 'until', '> 100.5\u00b0F', 'ANC > 1500/L', '(38.1\u00b0C) and', '2', 'Hold treatment', '50 mg/m\u00b2', 'ANC VI 1000/L)', 'until ANC', '> 1500/L', '3', 'Yes', 'N/A', 'Yes', 'ANC: absolute neutrophil count; N/A: not applicable; T: temperature', '5.1.2.4 Vinflunine Dose Modifications', 'In case of WHO/ECOG PS of 1 or ECOG PS of 0 and prior pelvic irradiation, vinflunine', 'treatment should be started at the dose of 280 mg/m\u00b2. In the absence of any hematological', 'toxicity during the first cycle causing treatment delay or dose reduction, the dose may be', 'increased to 320 mg/m\u00b2 every 21 days for the subsequent cycles. In subjects with moderate', 'renal impairment (40 mL/min CrCl < 60 mL/min), the recommended dose is 280 mg/m\u00b2 given', 'once every 21 day cycle. In subjects with renal impairment (30 mL/min VI CrCl < 40 mL/min),', 'the recommended dose is 250 mg/m\u00b2 given once every 21 day cycle.', 'The recommended dose of vinflunine is 250 mg/m\u00b2 given once every 21-day cycle in subjects', 'with mild liver impairment (Child-Pugh grade A). Please refer to local product label or', 'SmPC and institutional guidelines for further dose modifications.', 'The doses recommended in subjects > 75 years old are as follows:', 'in subjects at least 75 years old but less than 80 years, the dose of vinflunine to be given', 'is 280 mg/m\u00b2 every 21 day cycle.', 'in subjects 80 years old and beyond, the dose of vinflunine to be given is 250 mg/m\u00b2', 'every 21 day cycle.', 'In subjects who initiate vinflunine at 280 mg/m\u00b2 and who experience an AE requiring dose', 'modification, the dose should be reduced to 250 mg/m\u00b2 following the 1st occurrence and', 'resolution, and discontinued following a 2nd occurrence. In subjects who initiate vinflunine', 'at 250 mg/m\u00b2 and who experience an AE requiring dose modification, vinflunine should be', 'discontinued.', 'Cases of Posterior Reversible Encephalopathy Syndrome (PRES) have been observed after', 'administration of vinflunine. The typical clinical symptoms are, with various degrees:', 'neurological (headache, confusion, seizure, visual disorders), systemic (hypertension), and', '14 Sep 2020', 'Astellas', 'Page 63 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'gastrointestinal (nausea, vomiting). Radiological signs are white matter abnormalities in the', 'posterior regions of the brain. Vinflunine must be discontinued in subjects who develop', 'neurological signs of PRES. Dose modifications for subjects receiving vinflunine are detailed', 'below in', 'Table 8 Dose interruptions may last up to 6 weeks (2 cycles). Dose interruptions for', 'subjects who are deriving clinical benefit from treatment may be extended beyond 6 weeks, if', \"the subject's toxicity does not otherwise require permanent discontinuation. Please refer to\", 'the vineflunine (Javlor\u00ae) SmPC for additional information.', 'Table 8', 'Vinflunine Dose Modifications', 'Toxicity', 'Dose Adjustments', 'Initial Dose: Vinflunine 320 mg/m\u00b2', 'Initial Dose: Vinflunine 280 mg/m\u00b2', '2nd', '3rd', '2nd Consecutive', '1st Event', 'Consecutive', 'Consecutive', '1st Event', 'Event', 'Event', 'Event', 'Neutropenic fever', 'Vinflunine', 'Vinflunine', 'Discontinue', 'Vinflunine', 'Discontinue', '(defined as', '280 mg/m\u00b2', '250 mg/m\u00b2', 'treatment', '250 mg/m\u00b2', 'treatment', 'T> 100.5\u00b0F', '(38.1\u00b0C) and ANC', '< 1000/L)', 'Mucositis or', 'Constipation Grade', '2 > 5 days or', 'Grade 3 > any', 'duration 1', 'Cardiac ischemia', 'Discontinue', 'N/A', 'N/A', 'Discontinue', 'N/A', 'in patients with', 'treatment', 'treatment', 'prior history of', 'myocardial', 'infarction or', 'angina pectoris', 'ANC: absolute neutrophil count; N/A: not applicable; T: temperature', '1', 'National Cancer Institute Common Terminology Criteria for Adverse Events Grade 2 constipation is', 'defined as requiring laxatives, Grade 3 as an obstipation requiring manual evacuation or enema, Grade 4 as', 'an obstruction or toxic megacolon. Mucositis Grade 2 is defined as \"moderate,\" Grade 3 as \"severe\" and', 'Grade 4 as \"life-threatening.\"', '5.1.2.5 Paclitaxel Dose Modifications', 'Paclitaxel should not be administered to subjects with baseline neutrophil counts of less than', '1500 cells/mm\u00b3 Subjects should not be re-treated with subsequent cycles of paclitaxel until', 'neutrophils recover to a level > 1500 cells/mm\u00b3 and platelets recover to a level', '> 100000/mm\u00b3. Severe conduction abnormalities have been documented in < 1% of subjects', 'during paclitaxel therapy and in some cases requiring pacemaker placement. If subjects', 'develop significant conduction abnormalities during paclitaxel infusion, appropriate therapy', 'should be administered and continuous cardiac monitoring should be performed during', 'subsequent therapy with paclitaxel provided the subject does not require discontinuation.', '14 Sep 2020', 'Astellas', 'Page 64 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}